Title : The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands.

Pub. Date : 2021 Apr

PMID : 32745279






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CONCLUSIONS: Dapagliflozin is a cost-saving alternative to DPP-4 inhibitor when added to metformin and sulfonylurea. Metformin dipeptidyl peptidase 4 Homo sapiens